Indication

Maroteaux-Lamy syndrome

Maroteaux-Lamy syndrome, also known as mucopolysaccharidosis type VI (MPS VI), is a rare autosomal recessive lysosomal storage disease caused by a deficiency of the enzyme arylsulfatase B (N-acetylgalactosamine-4-sulfatase). Read more about Maroteaux-Lamy syndrome

1 drugs 1 manufacturers

Advertisement

Drugs that treat it

Common Maroteaux-Lamy syndrome therapies.

Showing 1–1 of 1 drugs

NAGLAZYME (galsulfase)

METABOLIC DISEASE ENZYME REPLACEMENT - MUCOPOLYSACCHARIDOSIS·MAROTEAUX-LAMY SYNDROME
BIOMARIN PHARMA
Filter & compare in the drug finder →Opens the drug finder with Maroteaux-Lamy syndrome preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Maroteaux-Lamy syndrome.

Maroteaux-Lamy syndrome, also known as mucopolysaccharidosis type VI (MPS VI), is a rare autosomal recessive lysosomal storage disease caused by a deficiency of the enzyme arylsulfatase B (N-acetylgalactosamine-4-sulfatase).

This enzymatic defect prevents the normal degradation of the glycosaminoglycan dermatan sulfate, leading to progressive intracellular accumulation and widespread tissue and organ dysfunction primarily beginning in childhood.

The multisystem clinical presentation is characterized by dysostosis multiplex, short stature, joint stiffness, coarse facial features, corneal clouding, hepatosplenomegaly, and cardiopulmonary complications such as heart valve disease and upper airway obstruction, typically without affecting cognitive development.

Personalize your experience

Follow Maroteaux-Lamy syndrome and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it